Straits Times Index
3,302.72 -11.33 (-0.34%) Nikkei
39,142.24 +72.56 (+0.19%) Hang Seng
19,421.11 -215.11 (-1.10%) FTSE 100
8,424.20 +3.94 (+0.05%) Bitcoin USD
71,027.38 +4,509.73 (+6.78%) CMC Crypto 200
1,512.87 +158.46 (+11.70%)
PFE Jan 2026 42.500 call
| Previous close | 0.6200 |
| Open | 0.6200 |
| Bid | 0.5900 |
| Ask | 0.7700 |
| Strike | 42.50 |
| Expiry date | 2026-01-16 |
| Day's range | 0.6200 - 0.6200 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.51k |
BenzingaPfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug, Tagrisso, infringed on Pfizer’s Wyeth unit’s patent rights. The jury found that AstraZeneca’s Tagrisso violated two patents held by Pfizer, which cover methods for treating cancer using the breast cancer drug Nerlynx. Also Read: Double Good News For AstraZeneca’s Breast Cancer Drugs. Puma Biotechnology Inc (
Barrons.comModerna and Novavax Hope for Early Launch of This Year’s Covid-19 Shots, Despite FDA Delay
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.
ZacksAstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
